Orphan designation follows QIDP and Fast Track status for CD101 IV SAN DIEGO - Headline of release should read: Cidara Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis (instead of Cidara Receives Orphan Drug Designation for Novel Echinocandin, CU101 IV, in Candidemia and Invasive Candidiasis) The corrected release reads: CIDARA RECEIVES ORPHAN DRUG DESIGNATION FOR NOVEL ECHINOCANDIN, CD101 IV, IN CANDIDEMIA AND INVASIVE CANDIDIASIS Orphan designation follows QIDP and…

Orphan designation follows QIDP and Fast Track status for CD101 IV SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its antifungal drug candidate, CD101 IV, for the treatment of candidemia and invasive candidiasis. Orphan drug designation of CD101 provides Cidara eligibility for seven years of market…

SAN DIEGO, Feb. 03, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to conduct a fireside chat from 2:40 p.m.- 3:00 p.m. EST. The conference is being held at the Waldorf…

-- Multiple Ascending Dose Study-Results Reinforce Excellent Safety and Tolerability - SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced data from the company's Phase 1 multiple ascending dose clinical trial of its antifungal drug candidate, CD101 IV, in healthy volunteers. CD101 IV is a novel, long-acting echinocandin that Cidara is developing for the treatment and prevention of serious, invasive fungal…

New Guidelines Recommend Echinocandins as First-Line Treatment for Deadly Fungal Infections in High-Risk Patients SAN DIEGO--(BUSINESS WIRE)--Dec. 21, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, commends the Infectious Diseases Society of America (IDSA) for new clinical guidelines that recognize the important role of echinocandins in the initial treatment of invasive fungal infections. Specifically, the guidelines recommend a shift from fluconazole to echinocandins as first-line treatment for invasive candidiasis and…

Single Ascending Dose Study-Results Demonstrate Excellent Safety and Tolerability and Support Once-Weekly IV Dosing -- -- Management to Host Webcast and Conference Call Tomorrow at 8:00 a.m. ET -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced positive data from the company's Phase 1 single ascending dose (SAD) clinical trial of its antifungal drug candidate, CD101 IV, in healthy volunteers. CD101 IV is a novel,…

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Jefferies 2015 Global Healthcare Conference in London. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 2:00 p.m. GMT (6:00 a.m. PT) on Thursday, November 19, 2015 in London. A live audio webcast and replay will be available in the Investors section of the company website at http://www.cidara.com. About Cidara Therapeutics Cidara is…

– New Data Support CD101’s Potential as a Potent Treatment for Serious Fungal Infections and Highlight Progress in Company’s Robust Antifungal Drug-Development Program – Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the presentation of preclinical data from studies demonstrating the unique attributes of Cidara’s lead antifungal drug candidate, CD101, supporting its potential use for treating serious fungal infections. The results are being…

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three and six months ended June 30, 2015 and provided an update on its corporate activities and product pipeline. Second Quarter 2015 and Subsequent Highlights Initiated Phase 1 Study of Lead Antifungal Product Candidate CD101 IV: In August, Cidara announced the initiation of a Phase 1, randomized, double-blind, dose-escalation study to determine the safety, tolerability,…

- Sixteen abstracts summarize evaluations of company's novel echinocandin CD101 and Cloudbreak™ immunotherapy platform - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today that results of nonclinical studies of two formulations of CD101, a novel echinocandin, will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, September 17-21, 2015.…